Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
Titel:
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
Auteur:
Gadgeel, Shirish M. Lew, Danika L. Synold, Timothy W. LoRusso, Patricia Chung, Vincent Christensen, Scott D. Smith, David C. Kingsbury, Laura Hoering, Antje Kurzrock, Razelle